Roche Holding | ROG - Net Income


Roche Holding reported CHF5.47B in Net Income for its fiscal semester ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Alcon AG USD 189M 28M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Fresenius EUR 361M 17M Dec/2025
Fresenius Medical Care EUR 118M 209M Mar/2026
Genmab DKK 31M 370M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
GRIFOLS EUR 73M 25.25M Mar/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 659M 340M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Orion EUR 90.4M 170.1M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Philips EUR 151M 244M Mar/2026
Recordati EUR 153.06M 35.75M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
UCB EUR 1.08B 608M Dec/2025